No Data
Hold Rating for Longboard Pharmaceuticals Amidst Acquisition Uncertainty and Speculative Risks
Express News | Longboard Pharmaceuticals Initiates Phase 3 Deep Ocean Study Evaluating Bexicaserin in Developmental and Epileptic Encephalopathies (Dees)
Longboard Pharmaceuticals Initiates Phase 3 DEEp OCEAN Study Evaluating Bexicaserin in Developmental and Epileptic Encephalopathies (DEEs)
Truist Financial Maintains Longboard Pharmaceuticals(LBPH.US) With Hold Rating
Longboard Pharmaceuticals Advances Neurological Treatments
Longboard Pharmaceuticals | 10-Q: Q3 2024 Earnings Report
No Data
No Data